Receive Our Newsletter

Hemophilia Bleeding Disorder Industry News

Biogen Idec and Sobi To Donate $1 Billion Units of Clotting Factor

Biogen Idec and Swedish Orphan Biovitrum AB announced their intent to produce one billion international units (IUs) of clotting factor therapy for humanitarian aid programs in the developing world at the World Federation of Hemophilia (WFH) 2014 World Congress. Initially, the companies have committed to donating up to 500 million IUs to the World Federation […]

CSL Opens World-Class Manufacturing Facility for Hemophilia Therapies

CSL Limited (ASX:CSL), parent company of CSL Behring which is based in King of Prussia, PA, today opened the CSL Behring Biotechnology Manufacturing Facility in Melbourne, Australia. The new facility, located adjacent to the site’s manufacturing plant for plasma products, is the centerpiece of CSL’s $250 million expansion at its Broadmeadows site and will play […]

Grifols Donates Coagulation Medicines to World Federation of Hemophilia

Grifols announced that it will donate up to 20 million units of coagulation therapies in each of the next three (3) years to the World Federation of Hemophilia (WFH). Grifols has been a proud supporter of the WFH and its noble efforts for nearly a decade – and this unprecedented product donation represents its largest […]

Reuters: Biogen Idec Hemophilia Drug Prices On Par With Older Therapies

Reuters – Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually. The move could pressure rivals such as Pfizer Inc to lower prices for existing hemophilia treatments, which provide […]

FDA approves First Long-Acting Recombinant Factor IX for Hemophilia B

The U.S. Food and Drug Administration today approved Alprolix, Coagulation Factor IX (Recombinant), Fc Fusion Protein, for use in adults and children who have Hemophilia B. Alprolix is the first Hemophilia B treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding. Alprolix is approved to help control […]

Wall Street Journal: The Hemophilia Drug at the Core of Baxter’s Pharma Spin-Off

Will the Baxter International bioscience spin-out become a bleeder by relying too heavily on hemophilia treatments? This is a key question being sorted out as the health care products company prepares to split into two entities next year. In 2013, Baxter’s hemophilia business amounted to $3.4 billion, or slightly more than 58 percent of the […]

CSL Behring Launches My Access™ Cost Share Program

People who are treating hemophilia A or von Willebrand Disease (VWD) with a CSL Behring therapy may now be eligible for financial support through the company’s My Access™ cost share program. My Access helps hemophilia A and VWD patients, who have private insurance, cover the out-of-pocket costs, up to $12,000, associated with treatment. “CSL Behring […]

Canada Approves Biogen Idec’s Long-Acting Alprolix™ for Hemophilia B

The Approval of ALPROLIX is First Significant Advance in Hemophilia B Treatment in More Than 17 Years Today Biogen Idec announced that Health Canada has approved ALPROLIX™ [Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. […]

PSI: CMS Final Rule On Ryan White Premium Assistance & Other State/Federal Programs

The Centers for Medicare and Medicaid Services (CMS) has posted an interim final rule (IFR) with comment period requiring Qualified Health Plans (QHPs) to “accept premium and cost-sharing payments made on behalf of enrollees by the Ryan White HIV/AIDS Program, other Federal and State government programs that provide premium and cost sharing support for specific […]

CMS Explanation in Response to PSI Letter to HHS Secretary

In response to letters by Patient Services Incorporated (PSI) and other patient advocacy groups, CMS has released a further explanation on the November 4, 2013, Frequently Asked Question (FAQ) document. As you will remember, CMS called into question the use of premium assistance, the FAQ stated: The Department of Health and Human Services (HHS) has […]

Page 5 of 1612345678910NextLast »

Assisting and Advocating for the Bleeding Disorders Community